The intrinsic pathway of coagulation:: a target for treating thromboembolic disease?

被引:156
作者
Gailani, D.
Renne, T.
机构
[1] Univ Wurzburg, Inst Clin Biochem & Pathbiochem, D-97080 Wurzburg, Germany
[2] Vanderbilt Univ, Dept Pathol, Nashville, TN USA
[3] Vanderbilt Univ, Dept Med, Nashville, TN USA
关键词
coagulation; factor XI; factor XII; intrinsic pathway; thrombosis;
D O I
10.1111/j.1538-7836.2007.02446.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The classic intrinsic pathway of coagulation is triggered by contact activation of the plasma protease factor (F)XII, followed by sequential proteolytic activation of FX1 and FIX. While a key mechanism for initiating coagulation in some clinically useful in vitro assays, the absence of abnormal bleeding associated with congenital FXII deficiency indicates that the intrinsic pathway is not important for normal blood coagulation in vivo. However, recent work with mice lacking FXII or FXI suggest that these proteases make important contributions to formation of pathologic intravascular thrombi. In models of arterial injury, FXII or FXI null mice are protected from formation of platelet rich occlusive thrombi to a degree similar to that seen in FIX deficient mice (a model for the severe bleeding disorder hemophilia B) or to wild type mice treated with high dose heparin. FXII or FXI deficiency does not appear to prevent the initiation of thrombus formation in these models, but instead causes significant thrombus instability that prevents occlusion of the vessel. These findings raise the possibility that a pathway similar or identical to the intrinsic pathway may operate in vivo under some circumstances. Furthermore, the disproportionate importance of FXII and FXI to occlusive thrombus formation compared to normal hemostasis makes these proteases attractive candidates for therapeutic inhibitors to treat or prevent thromboembolic disorders.
引用
收藏
页码:1106 / 1112
页数:7
相关论文
共 67 条
[1]   FACTOR-XI DEFICIENCY IN ASHKENAZI JEWS IN ISRAEL [J].
ASAKAI, R ;
CHUNG, DW ;
DAVIE, EW ;
SELIGSOHN, U .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :153-158
[2]   RETRACTED: Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa (Retracted article. see vol 282, pg 29067, 2007) [J].
Baglia, FA ;
Walsh, PN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (27) :20514-20519
[3]   RETRACTED: Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin (Retracted Article. See vol 46, pg 12886, 2007) [J].
Baglia, FA ;
Walsh, PN .
BIOCHEMISTRY, 1998, 37 (08) :2271-2281
[4]  
Baird TR, 2004, BLOOD, V104, p66A
[5]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[6]   REGULATION OF COAGULATION BY A MULTIVALENT KUNITZ-TYPE INHIBITOR [J].
BROZE, GJ ;
GIRARD, TJ ;
NOVOTNY, WF .
BIOCHEMISTRY, 1990, 29 (33) :7539-7546
[7]   PLASMINOGEN DEFICIENCY CAUSES SEVERE THROMBOSIS BUT IS COMPATIBLE WITH DEVELOPMENT AND REPRODUCTION [J].
BUGGE, TH ;
FLICK, MJ ;
DAUGHERTY, CC ;
DEGEN, JL .
GENES & DEVELOPMENT, 1995, 9 (07) :794-807
[8]   Blood coagulation in hemophilia A and hemophilia C [J].
Cawthern, KM ;
van't Veer, C ;
Lock, JB ;
DiLorenzo, ME ;
Branda, RF ;
Mann, KG .
BLOOD, 1998, 91 (12) :4581-4592
[9]   The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice [J].
Cheng, QF ;
Zhao, Y ;
Lawson, WE ;
Polosukhin, VV ;
Johnson, JE ;
Blackwell, TS ;
Gailani, D .
BLOOD, 2005, 106 (09) :3055-3057
[10]   Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation [J].
Chou, J ;
Mackman, N ;
Merrill-Skoloff, G ;
Pedersen, B ;
Furie, BC ;
Furie, B .
BLOOD, 2004, 104 (10) :3190-3197